6:00 p.m. CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), the clinical-stage biopharmaceutical company specializing in the development of innovative formulations of proteins and peptides for the treatment of diabetes and other metabolic diseases (the “Company”), announces today the exercise by IPF Partners (“IPF”) of part of its share subscription warrants (“BSA”), giving rise to the issue of 204,919 shares at a price of 2.44 euros per share, i.e. a total subscription price of around 500,000 euros.